T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutraliz...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/3/653 |
| _version_ | 1797608671512887296 |
|---|---|
| author | Ayumi Yoshifuji Masataro Toda Munekazu Ryuzaki Emi Oyama Kan Kikuchi Toru Kawai Ken Sakai Masayoshi Koinuma Kazuhiko Katayama Takashi Yokoyama Yuki Uehara Norio Ohmagari Yoshihiko Kanno Hirofumi Kon Toshio Shinoda Yaoko Takano Junko Tanaka Kazuhiko Hora Yasushi Nakazawa Naoki Hasegawa Norio Hanafusa Fumihiko Hinoshita Keita Morikane Shu Wakino Hidetomo Nakamoto Yoshiaki Takemoto |
| author_facet | Ayumi Yoshifuji Masataro Toda Munekazu Ryuzaki Emi Oyama Kan Kikuchi Toru Kawai Ken Sakai Masayoshi Koinuma Kazuhiko Katayama Takashi Yokoyama Yuki Uehara Norio Ohmagari Yoshihiko Kanno Hirofumi Kon Toshio Shinoda Yaoko Takano Junko Tanaka Kazuhiko Hora Yasushi Nakazawa Naoki Hasegawa Norio Hanafusa Fumihiko Hinoshita Keita Morikane Shu Wakino Hidetomo Nakamoto Yoshiaki Takemoto |
| author_sort | Ayumi Yoshifuji |
| collection | DOAJ |
| description | Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT<sup>®</sup>.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group. |
| first_indexed | 2024-03-11T05:46:50Z |
| format | Article |
| id | doaj.art-2fed93dc25684c4497166b9664361953 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T05:46:50Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2fed93dc25684c4497166b96643619532023-11-17T14:19:07ZengMDPI AGVaccines2076-393X2023-03-0111365310.3390/vaccines11030653T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with HemodialysisAyumi Yoshifuji0Masataro Toda1Munekazu Ryuzaki2Emi Oyama3Kan Kikuchi4Toru Kawai5Ken Sakai6Masayoshi Koinuma7Kazuhiko Katayama8Takashi Yokoyama9Yuki Uehara10Norio Ohmagari11Yoshihiko Kanno12Hirofumi Kon13Toshio Shinoda14Yaoko Takano15Junko Tanaka16Kazuhiko Hora17Yasushi Nakazawa18Naoki Hasegawa19Norio Hanafusa20Fumihiko Hinoshita21Keita Morikane22Shu Wakino23Hidetomo Nakamoto24Yoshiaki Takemoto25Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanDivision of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanFaculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo 164-8530, JapanLaboratory of Viral Infection Control, Ōmura Satoshi Memorial Institute, Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, JapanDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo 160-8582, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, JapanHumoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT<sup>®</sup>.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.https://www.mdpi.com/2076-393X/11/3/653COVID-19hemodialysisvaccinationvaccinecellular immunityhumoral immunity |
| spellingShingle | Ayumi Yoshifuji Masataro Toda Munekazu Ryuzaki Emi Oyama Kan Kikuchi Toru Kawai Ken Sakai Masayoshi Koinuma Kazuhiko Katayama Takashi Yokoyama Yuki Uehara Norio Ohmagari Yoshihiko Kanno Hirofumi Kon Toshio Shinoda Yaoko Takano Junko Tanaka Kazuhiko Hora Yasushi Nakazawa Naoki Hasegawa Norio Hanafusa Fumihiko Hinoshita Keita Morikane Shu Wakino Hidetomo Nakamoto Yoshiaki Takemoto T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis Vaccines COVID-19 hemodialysis vaccination vaccine cellular immunity humoral immunity |
| title | T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis |
| title_full | T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis |
| title_fullStr | T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis |
| title_full_unstemmed | T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis |
| title_short | T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis |
| title_sort | t cell response and antibody production induced by the covid 19 booster vaccine in japanese chronic kidney disease patients treated with hemodialysis |
| topic | COVID-19 hemodialysis vaccination vaccine cellular immunity humoral immunity |
| url | https://www.mdpi.com/2076-393X/11/3/653 |
| work_keys_str_mv | AT ayumiyoshifuji tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT masatarotoda tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT munekazuryuzaki tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT emioyama tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT kankikuchi tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT torukawai tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT kensakai tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT masayoshikoinuma tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT kazuhikokatayama tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT takashiyokoyama tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT yukiuehara tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT norioohmagari tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT yoshihikokanno tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT hirofumikon tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT toshioshinoda tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT yaokotakano tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT junkotanaka tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT kazuhikohora tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT yasushinakazawa tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT naokihasegawa tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT noriohanafusa tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT fumihikohinoshita tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT keitamorikane tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT shuwakino tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT hidetomonakamoto tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis AT yoshiakitakemoto tcellresponseandantibodyproductioninducedbythecovid19boostervaccineinjapanesechronickidneydiseasepatientstreatedwithhemodialysis |